🥦

Research Hub

Diet and Nutrition

What to eat, what to avoid, and the rigorous evidence behind every claim – including the great diet debates.

5 Articles
3 Filters
4 Formats Each
Imagine you have just started a new way of eating. You have cut out bread, pasta, and sugar. Instead, you are eating more healthy fats, like steak, eggs, and butter. You feel better than you have in years. Your "sugar levels" are great, your blood pressure is low, and you have plenty of energy. In your mind, you are "metabolically perfect." This means your body is doing a great job of handling energy and keeping you fit.
For a long time, most doctors and patients believed that heart disease was a one-way street. Once your arteries started to clog up with  plaque , the goal was simply to slow down the decline. We treated it like a rust problem on an old car—you can’t really get rid of the rust; you just try to paint over it or keep it from spreading too fast. It felt like an unstoppable force of aging.But what if heart disease wasn’t a life sentence? Imagine your arteries are like a  garden hose .
Imagine a doctor sitting in a dark room, peering through a powerful microscope at a tiny blob of yellow fat. For almost a hundred years, doctors looked at these blobs and thought they had found the "bad guy" causing heart disease. They called it cholesterol, and they believed that simply having too much of this "yellow grease" in your blood was the reason pipes in the body got clogged.
Heart Disease and The Fish-Oil Confusion, the Vascepa Controversy, and What the Evidence Actually Shows For decades, cardiovascular medicine has been dominated by a single, often misunderstood narrative: “Fish oil is good for your heart.” This belief has become so culturally entrenched that it blurs the line between evidence-based cardiology and retail wellness, leading millions of people to consume omega-3 supplements daily in the hope of reducing cardiovascular risk.
Introduction: Challenging the Paradigm of Permanent Progression The management of coronary artery disease (CAD) has traditionally been viewed through the lens of “risk management.” In this paradigm, pharmacological interventions such as statins and procedural approaches such as Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) are deployed to slow the expected progression of disease. However, these approaches primarily address late-stage manifestations—the “downstream” consequences—rather than the “upstream” cellular and molecular drivers of plaque formation and instability.
Receive the latest news

Subscribe To Our Newsletter

Get notified about new articles.